<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30157910</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>30</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1745-6215</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>19</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Trials</Title>                <ISOAbbreviation>Trials</ISOAbbreviation>            </Journal>            <ArticleTitle>Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.</ArticleTitle>            <Pagination>                <MedlinePgn>467</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-018-2851-9</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nitrogen containing bisphosphonates such as zoledronic acid (ZA) are known to contain certain anti-cancer properties. These have been investigated in the past in various cancers such as breast, prostate and colon. ZA in particular has shown promising results in pre-clinical studies. We propose a multicentre double-blind randomised controlled feasibility study to assess the recruitment and acceptability of ZA/placebo alongside chemotherapy in malignant pleural mesothelioma (MPM).</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients will be recruited for a 13-month period from October 2016 to November 2017. Eligible patients will be identified via the regional mesothelioma multidisciplinary team meeting. Those who receive chemotherapy will be randomised to receive either ZA or placebo alongside their chemotherapy. Those who decline chemotherapy will be offered to join the trial on the non-randomised open-labelled arm of the trial. Patients will receive a maximum of six cycles of ZA/placebo, at three-weekly cycles. All patients will be followed up for six months from randomisation. Semi-structured interviews to gather data on acceptability of trial procedures, tolerability of ZA and other relevant information will take place after the participants have completed their six cycles of treatment. For a better understanding about non-participation in mesothelioma trials we also aim to interview those who decline to take part in the trial.</AbstractText>                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The qualitative and quantitative data gathered in this feasibility trial will hopefully pave the way to designing a robust full phase III trial to investigate the potential synergistic effect of ZA and current standard treatment for MPM, cisplatin-pemetrexed combination chemotherapy.</AbstractText>                <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ISRCTN Registry, ISRCTN45536692 . Registered on 9 August 2016. EudraCT no. 2015-004433-26.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>de Fonseka</LastName>                    <ForeName>Duneesha</ForeName>                    <Initials>D</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0060-9671</Identifier>                    <AffiliationInfo>                        <Affiliation>Academic Respiratory Unit, University of Bristol, Bristol, UK. duneesha@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morley</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Respiratory Research Unit, North Bristol NHS Trust, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Stadon</LastName>                    <ForeName>Louise</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Respiratory Research Unit, North Bristol NHS Trust, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Keenan</LastName>                    <ForeName>Emma</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Respiratory Research Unit, North Bristol NHS Trust, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Walker</LastName>                    <ForeName>Steven</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Academic Respiratory Unit, University of Bristol, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smith</LastName>                    <ForeName>Sarah</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>North Bristol NHS Trust, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harvey</LastName>                    <ForeName>John E</ForeName>                    <Initials>JE</Initials>                    <AffiliationInfo>                        <Affiliation>Academic Respiratory Unit, University of Bristol, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cox</LastName>                    <ForeName>R Ashley</ForeName>                    <Initials>RA</Initials>                    <AffiliationInfo>                        <Affiliation>Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dangoor</LastName>                    <ForeName>Adam</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Bristol Haematology and Oncology Centre, Bristol Royal Infirmary, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Comins</LastName>                    <ForeName>Charles</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Bristol Haematology and Oncology Centre, Bristol Royal Infirmary, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rogers</LastName>                    <ForeName>Christine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Trials and Evaluation Unit, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Edey</LastName>                    <ForeName>Anthony</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Radiology Department, North Bristol NHS Trust, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Addeo</LastName>                    <ForeName>Alfredo</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Bristol Haematology and Oncology Centre, Bristol Royal Infirmary, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Maskell</LastName>                    <ForeName>Nick A</ForeName>                    <Initials>NA</Initials>                    <AffiliationInfo>                        <Affiliation>Academic Respiratory Unit, University of Bristol, Bristol, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>PB-PG-1014-35052</GrantID>                    <Agency>Research for Patient Benefit Programme</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Trials</MedlineTA>            <NlmUniqueID>101263253</NlmUniqueID>            <ISSNLinking>1745-6215</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Malignant pleural mesothelioma</Keyword>            <Keyword MajorTopicYN="N">Mesothelin</Keyword>            <Keyword MajorTopicYN="N">Mesothelioma</Keyword>            <Keyword MajorTopicYN="N">PET-CT</Keyword>            <Keyword MajorTopicYN="N">Zoledronic acid</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>10</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30157910</ArticleId>            <ArticleId IdType="doi">10.1186/s13063-018-2851-9</ArticleId>            <ArticleId IdType="pii">10.1186/s13063-018-2851-9</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>